Dr. Brian Wolpin discusses updated safety and efficacy results from the Phase 1 study of RMC-6236, a RAS(ON) multi-selective inhibitor, highlighting its promising activity, manageable safety profile, and encouraging survival outcomes in patients […]

Panelists discuss how the future treatment landscape for transplant-ineligible/deferred NDMM is evolving toward more personalized approaches with quadruplet regimens, while acknowledging remaining challenges in optimizing duration of therapy, […]

Panelists discuss how the CIRCULATE study’s GALAXY results demonstrate the potential impact of circulating tumor DNA analysis in guiding adjuvant therapy decisions for stage II colon cancer patients, though further validation is needed before […]

Dr. Jorge E. Cortes provides a comprehensive overview of the 5-year follow-up results from the Phase 2 OPTIC study, showcasing the long-term efficacy, safety, and mutational analysis of ponatinib in patients with chronic-phase chronic myeloid […]

Marcel van den Brink, MD, PhD, discusses a high-fiber dietary intervention for early-stage plasma cell disorders designed for multiple myeloma

Panelists discuss how the approval of afamitresgene autoleucel (afami-cel) as the first T-cell receptor (TCR) therapy marks a pivotal milestone that could accelerate development and acceptance of TCR-based treatments by establishing regulatory […]

Panelists discuss how the combination of zanubrutinib plus venetoclax in arm D of the SEQUOIA trial contributes to understanding the potential role of BTK inhibitor and BCL2 inhibitor combinations in frontline CLL treatment.

Dr. Shirley D’Sa highlights the 5.8-year follow-up results from the ASPEN long-term extension study, demonstrating the durable efficacy, deepening responses, and favorable safety profile of zanubrutinib in patients with Waldenström […]

Neal Shore, MD, FACS, discusses implications of data for sasanlimab plus BCG in BCG-naive, high-risk non–muscle-invasive bladder cancer.

Marlise Luskin, MD, MSCE, discusses the treatment paradigm for relapsed/refractory ALL and research seeking to integrate agents into the frontline setting

Dr. Jacob D. Soumerai presents updated data from the BGB-11417-101 study, highlighting the high efficacy, tolerability, and sustained minimal residual disease clearance achieved with the novel combination of sonrotoclax and zanubrutinib in patients […]

Benjamin P. Levy, MD, shares insight on current challenges with TROP2-directed antibody-drug conjugates in NSCLC.

Ian Krop, MD, PhD, spotlights emerging HER2-directed agents of interest for pretreated patients with HER2-positive breast cancer.

Findings will help identify patients with breast, ovarian, pancreatic, or prostate cancer who may benefit from targeted therapies.

Treatment with synthetic hypericin for up to 12 months produced responses in early-stage cutaneous T-cell lymphoma.

Savolitinib has received full NMPA approval for locally advanced/metastatic non–small cell lung cancer with MET exon 14 skipping alterations.

Yousef Zakharia, MD, discusses the evolving use of checkpoint inhibitors and emerging triplet regimens in clear cell renal cell carcinoma.

Panelists discuss the DESTINY-Breast12 trial, reviewing its study design, rationale, and key efficacy and safety findings in HER2-positive metastatic breast cancer patients with brain metastases, focusing on differences in outcomes between patients […]

Panelists discuss how the latest NCCN guidelines for targeted therapies and biomarker testing in advanced/metastatic breast cancer highlight the importance of biomarker-driven approaches, with particular emphasis on the need for next-generation […]

Pedro Barata, MD, details factors affecting treatment selection with biomarker-based approvals and highlights questions regarding genetic testing.

Adjuvant nivolumab plus chemoradiotherapy improved disease-free survival in resected, locally advanced head and neck squamous cell carcinoma.